Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | BLM | P54132 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | NOS3 | P29474 | 1/20 | 0.62 |
| ▸ | NOS1 | P29475 | 1/20 | 0.62 |
| ▸ | NOS2 | P35228 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | CFD | P00746 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30557808 | 1.00 | LMNA (0.62) | LMNABLMCYP1A2ADRA2ATSHR | |
| SCHEMBL62706 | 0.85 | LMNA (0.58) | LMNABLMCYP1A2ADRA2ATSHR | |
| SCHEMBL30908765 | 0.85 | LMNA (0.58) | LMNABLMCYP1A2ADRA2ATSHR | |
| SCHEMBL1202554 | 0.78 | F2 (0.56) | LMNAF2CFDPARP1ALDH1A1 | |
| SCHEMBL31607092 | 0.78 | F2 (0.56) | F2CFDPARP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL31607095 | 0.78 | F2 (0.56) | F2CFDPARP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12324556 | 0.78 | F2 (0.56) | LMNABLMCYP1A2ADRA2ATSHR | |
| SCHEMBL3435898 | 0.78 | NOS1 (0.62) | LMNANOS3NOS1NOS2F2 | |
| SCHEMBL7422358 | 0.78 | F2 (0.56) | LMNABLMCYP1A2ADRA2ATSHR | |
| SCHEMBL30549739 | 0.78 | F2 (0.56) | LMNAF2CFDHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118727475-B | Room temperature salt-free rapid reactive dyeing and recycling method suitable for cellulose fibers | 绍兴劲草化工有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-119098205-A | Nitrogen-doped porous carbon-loaded cobalt monoatomic catalyst and preparation method and application thereof | 南京理工大学 | 2024-12-10 | — | — | CN | claimed |
| CN-118727475-A | Room temperature salt-free rapid reactive dyeing and recycling method suitable for cellulose fibers | 绍兴劲草化工有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-117603144-A | Synthesis method of polysubstituted quinazolinone | 常熟泓德生物科技有限公司 | 2024-02-27 | — | — | CN | claimed |
| EP-3947667-A1 | MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| CN-113993997-A | Modified cleaving enzymes, uses thereof and related kits | ENCODIA 公司 | 2022-01-28 | — | — | CN | claimed |
| CN-110372611-B | Method for selectively synthesizing polysubstituted dihydro quinazolinone or quinazolinone | 常熟理工学院 | 2021-05-04 | — | — | CN | claimed |
| WO-2020198264-A1 | MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2020-10-01 | — | — | WO | claimed |
| CN-110372611-A | A kind of method of the polysubstituted dihydroquinazoline ketone of selectivity synthesis or quinazolinone | 常熟理工学院 | 2019-10-25 | — | — | CN | claimed |
| JP-5209132-A | — | — | None | — | — | JP | disclosed |
| EP-4727923-A1 | TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4730479-A2 | FLAME-RETARDANT NON-AQUEOUS ELECTROLYTIC SOLUTION AND SECONDARY BATTERY USING SAME | Kyoto University (JP) | 2026-04-22 | — | — | EP | disclosed |
| US-20260098012-A1 | TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-4710502-A | THROMBOXANE SYNTHETASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1987-12-01 | — | — | US | disclosed |
| US-4684654-A | THROMBOXANE SYNTHETASE INHIBITORS, HYPOTENSIVES | AMERICAN CYANAMID COMPANY (US) | 1987-08-04 | — | — | US | disclosed |
| EP-0218999-A2 | New quinazoline derivatives, process for their production and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-04-22 | — | — | EP | disclosed |
| US-4659718-A | VASODILATION | THE BOOTS COMPANY PLC (GB) | 1987-04-21 | — | — | US | disclosed |
| EP-0135367-A1 | Therapeutic agents | The Boots Company PLC (GB) | 1985-03-27 | — | — | EP | disclosed |
| US-3984562-A | TREATING ANXIETY | AMERICAN CYANAMID COMPANY (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098012-A1 | TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA | CD47, SLC11A2, G6PD | LMNA 297/4885BLM 4619/4885CYP1A2 1169/4885 |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | CRBN, CD4, ICOS | LMNA 2916/4885BLM 4143/4885CYP1A2 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.